Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): A critical view

Cancer Treatment Reviews

Volumn 39, Issue 3, 2013, Pages 270-274

  Fazio, Nicola ^a   Spada, Francesca ^a   Giovannini, Monica ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Carboplatin; Chemotherapy; Cisplatin; Etoposide; Gastroenteropancreatic; GEP; Irinotecan; NEC; NET; Neuroendocrine carcinoma

Indexed keywords

CARBOPLATIN; CD34 ANTIGEN; CISPLATIN; CYTOKERATIN 20; CYTOKERATIN 7; ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM; GEMCITABINE; IRINOTECAN; KI 67 ANTIGEN; OCTREOTIDE; OXALIPLATIN; STEM CELL FACTOR RECEPTOR; TEMOZOLOMIDE; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR PAX5;

ANEMIA; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; GOLD STANDARD; HUMAN; IMMUNOREACTIVITY; INFECTION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROENDOCRINE CARCINOMA; NEUROENDOCRINE TUMOR; NEUTROPENIA; OTOTOXICITY; PANCREATIC NEUROENDOCRINE TUMOR; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NEUROENDOCRINE; GASTROINTESTINAL NEOPLASMS; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84873997406     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.06.009     Document Type: Review

References (43)

1. Oberg K. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches. Curr Opin Oncol 2012; Apr 15: [Epub ahead of print].
2. Yao J.C., Hassan M., Phan A., et al. One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol 2008, 26:3063-3072.
3. Lepage C., Rachet B., Coleman M.P. Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology 2007, 132:899-904.
4. Pape U.F., Berndt U., Mueller-Nordhorn J., et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008, 15:1083-1097.
5. Modlin I.M., Oberg K., Chung D.C., et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008, 9:61-72.
6. Bosman F.T., Carneiro F. WHO classification of tumours, pathology and genetics of tumours of the digestive system 2010, IARC Press, Lyon.
7. Bernick P.E., Klimstra D.S., Shia J., et al. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum 2004, 47:163-169.
8. Brenner B., Shah M.A., Gonen M., et al. Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer 2004, 90:1720-1726.
9. Burke A.B., Shekitka K.M., Sobin L.H. Small cell carcinomas of the large intestine. Am J Clin Pathol 1991, 95:315-321.
10. Strosberg J.R., Coppola D., Klimstra D.S., et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 2010, 39:799-800.
11. Ahlman H., Nilsson O., McNicol A.M., et al. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology 2008, 87:40-46.
12. World Health Organization. International histological classification of tumors: histologic typing of endocrine tumors 2000, Springer, Berlin. E. Solcia, G. Klöppel, L.H. Sobin (Eds.).
13. Faggiano A, Ferolla P, Grimaldi F, et al. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: The Net Management Study. J Endocrinol Invest 2011; Nov 9 [Epub ahead of print].
14. Mitry E., Rougier The treatment of undifferentiated neuroendocrine tumors. Crit Rev Oncol Hematol 2001, 37:47-51.
15. Johnson L.A., Lavin P., Moertel C.G., et al. Carcinoids: the association fo histologic growth pattern and survival. Cancer 1983, 51:882-889.
16. Hanna N., Bunn P.A., Langer C., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006, 24(13):2038-2043.
17. Moertel C.G., Kvols L.K., O'Connel M.J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer 1991, 68:227-232.
18. Mitry E., Baudin E., Ducreaux M., et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999, 81:1351-1355.
19. Fjallskog M.L.H., Granberg D.P.H., Welin S.L.W., et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001, 92(5):1101-1107.
20. Iwasa S., Morizane C., Okusaka T., et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol 2010, 40(4):313-318.
21. Mavroudis D., Papadakis E., Veslemes M., et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatinetoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001, 12:463-470.
22. Hainsworth J.D., Apigel D.L., Greco A. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006, 24:3548-3554.
23. Arnold R., Simon B., Wield M. Treatment of neuroendocrine GEP tumours with somatostatin analogues. Digestion 2000, 62(Suppl. 1):84-91.
24. Lamberts S.W.J., Krenning E.P., Reubi J.C. The role of somatostain and its analogs in the diagnosis and treatments of tumors. Endocrinol Rev 1991, 12:450-482.
25. Saltz L., Trochanowsky G., Buckley M., et al. Octreotide as an antineoplastic agent in the treatment of functional and non/functional neuroendocrine tumours. Cancer 1993, 72:244-248.
26. Arnold R., Trautmann M.E., Creutzfeldt W., et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumors. Gut 1996, 38:430-438.
27. Di Bartolomeo M., Bajetta E., Buzzoni R., et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer 1996, 77:402-408.
28. Aparicio T., Ducreaux M., Baudin E., et al. Antitumor activity of somatostatin analogues in progressive metastatic neuroendocrine tumors. Eur J Cancer 2001, 37:1014-1019.
29. Brizzi M.P., Berruti A., Ferrero A., et al. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer 2009, 3:388.
30. Correale P., Sciandivasci A., Intrivici C., et al. Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation. Br J Cancer 2007, 96:1343-1347.
31. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012; [Epub ahead of print].
32. Di Meglio G., Massacesi C., Radice D., et al. Carboplatin with etoposide in patients with extrapulmonary " aggressive" neuroendocrine carcinoma" J Clin Oncol 2010, 28. [Suppl.; Abstr. e13072].
33. Okita N.T., Kato K., Takahari D., et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer 2011, 14:161-165.
34. Yagamuchi T., Machida N., Kasuga A., et al. Multicenter retrospective analysis of systemic chemotherapy in poorly differentiated neuroendocrine carcinoma of the digestive system. J Clin Oncol 2012, 30(Suppl. 4). [Abstr. 274].
35. Bajetta E., Catena L., Procopio G., et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?. Cancer Chemother Pharmacol 2007, 59:637-642.
36. Turner N.C., Strauss S.J., Sarker D., et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010, 1-7.
37. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011 Mar 31, [Epub ahead of print].
38. Yachida S., Vakiani E., White C.M., et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 2012, 36:173-184.
39. Takubo K., Nakamura K., Sawabe M., Arai T., Esaki Y., Miyashita M., et al. Primary undifferentiated small cell carcinoma of the esophagus. Hum Pathol 1999, 30:216-221.
40. Brenner B., Tang L.H., Klimstra D.S., et al. Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol 2004, 22:2730-2739.
41. La Rosa S., Marando A., Furlan D., et al. Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol 2012, 36:601-611.
42. Sorbye H., Welin S., Langer S.W., et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: The NORDIC NEC study. J Clin Oncol 2012, 30. [Suppl.; Abstr. 4015].
43. Scoazec J.Y., Couvelard A., Monges G., et al. Well-differentiated grade 3 digestive neuroendocrine tumors: Myth or reality? The PRONET study group. J Clin Oncol 2012, 30. [Suppl.; Abstr. 4129].